Finally, in mice, the combination of anti-CD96 mAb with other immune checkpoint inhibitors (i.e., CTLA-4 and PD-1) or chemotherapy (e.g., doxorubicin and gemcitabine) demonstrated to be beneficial, suggesting a supportive role for CD96 blockade in combination with other anti-cancer therapies [107,114]. This evidence concerns the gene PDCD1 and cancer.